wingo tool Eli Lilly's "cancer-free" RET inhibitor clinical data officially published in NEJM Well-known pharmaceutical companies respond to investigation of medical representatives Merck's SGLT-2 ...
The Book Of Hor pdf R&D Daily丨Hengrui Submits Two New Indications for PD-1 for Marketing Approval Alphamab Oncology's PD-L1/CTLA-4 dual antibody KN046 received approval for Phase II clinical trial ...
The Carroll County Community Foundation is pleased to announce the recipient of the 2025 Lilly Endowment Community ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
AHA shares feedback in response to the Centers for Medicare & Medicaid Services’ information collection request (ICR) regarding the Medicare Transaction Facilitator (MTF) and the Medicare drug ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight loss drugs.
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback